FibroGen announces acceptance by China FDA of Roxadustat NDA for treatment of anemia
FibroGen announced the CFDA has accepted the company’s recently submitted New Drug Application for registration of roxadustat, a novel oral investigational treatment for anemia in dialysis-dependent CKD and non-dialysis-dependent CKD patients. October 18, 2017